Ricin from Castor Beans: Toxic Bioweapon or Cancer Treatment?

In 1998, researchers stated “The once-maligned castor bean may be the next heavy hitter in cancer treatment,” yet it is still on the drawing board.
Kabar/Shutterstock
Updated:
0:00

In a perfect world, we would have eradicated cancer by now. I wish this were so, as even in my small, personal community, two women have been diagnosed with cancer just this past month—one in her 20s with primary B-cell lymphoma, and one in her 50s with endometrial cancer. Many lives are turned upside down by these diagnoses. Sadly, my list of family and friends who suffer from this debilitating disease could go on. I am certain, this is the case for many of us.

Therefore, it is crucial for everyone to take preventative measures, including a healthy lifestyle, well-balanced nutrition, physical activity, positive relationships, adequate rest, and spiritual exercises for the soul.

However, often such measures do not suffice, and despite all efforts the disease may already be present or on its way. Should it befall us, we may find options outside the box of conventional treatment and look to natural alternatives, seek conventional treatment, or employ a combination of both.

Story continues below advertisement

The deadly poison ricin, found within the seeds of castor beans, may be one of those options.

7 Decades of Research

The first report about ricin’s “necrosing or clastic” effects on sarcomas, a type of cancer that befalls different locations in the body, was published in a French journal in 1951.
In 1977, a comparative study about ricin as a possible inhibitory agent was released in the journal Cancer Research. In it, scientists transplanted murine tumors (solid tumors or human cancer cells) into mice.
More than 20 years later, in 1998, researchers at Texas Tech University stated that “the once-maligned castor bean may be the next heavy hitter in cancer treatment.”
Another twenty years later, in 2019, a study published in the Asian Pacific Journal of Cancer Prevention remarked on ricin’s chemical potential to manage the disease. However, researchers noted that so far, the “application of ricin in cancer treatment is very limited because of its non-specificity.”
Story continues below advertisement
Seven decades of scientific investigations into ricin as a human cancer treatment come to the same conclusion—the naturally poisonous substance has potential as a cytotoxin. Yet, it still has not been developed for use in mainstream cancer therapies.

A Plant-Cytotoxin Spreads Seeds of Hope

Ricin, a protein that binds to carbohydrates, is the toxic byproduct from the castor bean accruing during castor oil production. According to the Centers for Disease Control and Prevention, ricin has been used in “experimental” research for anti-cancer medicine.
Ricin has also been utilized to develop immunotoxins. These have the potential to kill unwanted cells, even of a cancerous nature. Such anticancer therapies use immunoconjugates (types of antibodies that join to another molecule). Though they are only minimally toxic and “gave promising results in clinical trials,” these immunoconjugates portrayed limitations as well, states a 2019 article in the journal Toxins.

Target Cancer Therapy

The limiting factors of this therapy seem to lie in its variable components. Immunoconjugates are comprised of three separate parts, as outlined in the Nature Reviews Clinical Oncology:
  1. “An antibody that binds to a cancer cell antigen with high specificity
  2. An effector molecule that has a high capacity to kill the cancer cell
  3. A linker that will ensure the effector does not separate from the antibody during transit and will reliably release the effector to the cancer cell or tumor stroma.”
In short, there is need for an antibody, a therapeutic agent, and a connector. The difficulty is that all variables must cooperate to result in a cancer-curing ensemble.

Ricin–A Therapeutic Agent and ‘Magic Bullet’

In cancer treatment, there are several types of therapeutic entities —pharmaceutical drugs, radioisotopes (elements that release radiation during their break-down processes), and natural toxins such as Shiga toxin (a bacterial toxin) or the castor bean’s ricin. For any of them to work the transport mechanisms of the medication to its target location must be ensured.
A 2015 review in Tumour Biology states that “over the years” ricin has shown “great potential as an anti-cancer agent.” It applies its action by a process called apoptosis (the body’s natural way of ridding itself of unneeded or abnormal cells).

The poison displays the ability to induce a form of “programmed apoptosis,” or “programmed cell death,” in cancer cells, which otherwise often block this progression.

Story continues below advertisement

According to the review, newly developed nanotechnology could be critical for further development of this ricin-based anti-cancer technique.

A 2022 animal study genetically combined ricin’s toxin A chain (RTA), affibodies (that mimic natural antibody-binding abilities), and a signal short ring of amino acids (peptide) to develop specific anti-cancer recombinant immunotoxins (RITs).
Researchers concluded that this strategy could “offer new possibilities” in the development of “magic bullets that can effectively suppress the growth of tumors which are resistant to conventional immunotoxins and anti-cancer drugs.”

Application of Ricin in Various Cancer Treatments

Like other plants, Ricinus communi’s plant tissue contains lectins, some of which are potent toxins. They work as part of the plant’s natural defense mechanism against herbivores and phytophagous insects.
This gives hope for the treatment of various types of cancers.

Lymphoma

Ricin’s potent activity as an immunotoxin—specifically against Hodgkin’s lymphoma cells—was detected in animal models and in vitro. A clinical trial in humans followed previous in-depth research and indicated “moderate efficacy in heavily pretreated refractory patients.” Results were published in the European journal Annals of Oncology.
Story continues below advertisement
In another human clinical trial, 44 individuals suffering from advanced-stage non-Hodgkin’s lymphomas were evaluated during and after a combination treatment of chemotherapy and subsequent immunotoxin treatment.

Fifty-seven percent experienced a “complete response” to the therapy—though only three patients achieved that result through the application of the immunotoxin. Nevertheless, researchers seem pleased with the outcome of the trial, as “remissions appear quite durable (> 4 years) in about 40% of the complete responders.”

In a different study, seven patients who suffered from “high-risk acute T-cell lymphoblastic leukemia” and six individuals diagnosed with T-cell lymphoma were treated with ricin; that is, their bone marrow was cleansed in-vitro by employing the ricin A-chain immunotoxin.

Tests showed that this purging of “bone marrow in high-risk T-cell malignancies” resulted in a complete formation of blood cellular components (hematopoiesis) and a delayed reconstruction of the immune system.

Story continues below advertisement
The relapse-free survival rate reached 61 percent in three years.

Breast Cancer

The European Journal of Pharmacology featured a 2023 study, in which in-vitro evaluations assessed biological activities and the efficacy of recombinant proteins, such as the ricin toxin A chain (RTA).

The novel immunotoxin demonstrated significant anti-proliferative and pro-apoptotic effects against cancer cells—both effects determine the rate of cell death by apoptosis. The MTT cytotoxicity assay—a tool to measure cell viability—revealed that cancer cell lines were less capable of survival after treatment.

A 2021 study showed promising clinical effects after reviewing HER2 tumor biomarkers (biological molecules in the body specific to breast cancer) and their reaction to conjugates and immunotoxins, such as ricin.
However, although researchers conclude that the therapeutic impact of the treatment may be beneficial, possible side effects of this novel approach must still be evaluated.

Melanoma and Other Cancers

Melanoma cancer cells also respond favorably to ricin as a therapeutic agent. This was indicated by an in-vitro study that displayed the plant toxin’s strong poisonous qualities. The tumor colonies, which were formed in soft agar, greatly diminished in size during this treatment with a low dose of purified total ricin.
Story continues below advertisement

The application increased apoptosis as well, thus the researchers conclude that ricin “has potential to be used as a drug for melanoma treatment”—all, in addition to its high ranking on the natural toxins list.

Another in-vitro study published in the Asian-Pacific Journal of Cancer Prevention arrives at the same results.

Researchers encapsulated ricin with a liposome. The ricin-liposome complex was engulfed by tested cancer cells. This process limited the cells’ capability to migrate and decreased their invasion potential, as well as their ability to form tumors. Hence, the formulations were seen as “great anticancer properties [in] melanoma and other cancers.”

Ricin has long been reported for utilization in various cancer treatments, such as “leukemia, breast cancer, and cervical cancer,” according to seven studies mentioned in the publication.

Ricin in General Immunotoxin Therapy

Ricin toxin comes in two subunits: ricin toxin A (RTA) and ricin toxin B (RTB). The two function differently, with either a polypeptide chain A or a polypeptide chain B. “RTB attaches onto the cell surface, while RTA enters the cell, attaching to ribosome and inhibiting protein synthesis,” explains a review.
Story continues below advertisement
“A single RTA biomolecule is able to inactivate 1,500–2,000 ribosomes per minute, ultimately leading to cell death,” which is what encourages researchers to see ricin as a general immunotoxin in cancer therapy, leading to specific and irreversible inhibition of protein synthesis in eukaryotic cells.

Immunogenicity as a Possible Side-Effect

Our body naturally reacts to and fights off any proteins that enter its systems. So too, does the body answer with an immune response when immunotoxin therapy is administered. This reaction is called immunogenicity and might provoke undesired drawbacks to the treatment itself.

On one hand, the induced toxic protein may lose its power. On the other hand, repeated injections might provoke an even stronger response of the immune system, making doctors hesitant to multiple applications.

“This problem is so serious that immunogenicity observed with some therapeutic molecules is considered as an obstacle to further development into clinical use,” outlines Chapter 12 in Maddalena de Virgilio’s “Harnessing the Destructive Power of Ricin to Fight Human Cancer.”
On the other hand, conventional treatment comes with its own myriad of possible side effects. Literally, we must “pick our poison” wisely.

Limitations in Personal Treatment

At first sight, the use of ricin in cancer treatment might seem like a promising strategy. However, there are cons.
Story continues below advertisement
Sole ricin is a highly toxic substance and can lead to quick lethal outcomes. Therefore, ricin cannot be sold commercially.

Furthermore, the compound needs purification and isolation directly from the bean to be studied correctly and applied medicinally.

Lastly, though ricin is a natural substance, there is nothing natural about the process of using ricin as medicine. Most applications involve recombinant DNA technology, molecular cloning, genetic engineering, and other modifications on a laboratory scale.
Simply ingesting castor oil cannot bring the desired cure, as the heated extraction process inactivates the water-soluble ricin. However, the elimination of ricin in this procedure makes castor oil safe for other, mostly external health applications.
Story continues below advertisement
Certainly, ricin is not as “easy” an alternative cancer treatment as the similarly controversial ivermectin, which The Epoch Times featured in a recent article.

Ricin Toxin as Warfare Agent

According to the Centers for Disease Control and Prevention, the highly potent compound ricin is water-soluble, without a taste or smell, stable in an ambient environment, and not affected much by heat or extreme cold. As such, it can be used as a powder, a breathable mist, in the form of a pellet, or be served in a drink with lethal results—for which there are no available antidotes.

Conditional to the route of contact, first symptoms can come immediately and worsen progressively over the following 4–36 hours. Death may occur within 36–72 hours of contact, depending on the significance of the exposure.

This sounds like a perfect application in bioterrorism, and indeed, ricing toxin belongs to the “B group of biological warfare agents,” as a previously mentioned review of ricin in the journal Toxicology states. “Inhalation is the most potent route of entry,” whereas oral ingestion may be non-lethal and less toxic, expresses the paper.

To End on a Positive Note

While ricin’s high cytotoxicity and ease of production may make it tempting to terrorists, it is also enticing to doctors and researchers, who strive to harness this plant’s destructive power and channel it toward an honorable cause—a real cure for cancer.
Seventy years of research will be followed by many more, and may someday result in more hope for families and communities, and bring us all a tiny step closer to a perfect world.
Alexandra Roach
Alexandra Roach
Author
Alexandra Roach is a board-certified holistic health practitioner, herbalist, and movement teacher who has also worked as a journalist, TV news anchor, and author. She has earned citations from U.S. Army commanders for her work with military personnel and writes with a broad perspective on health.
Related Topics